A natural plant compound reduced pain by boosting endocannabinoids without binding to cannabinoid receptors | Research

The takeaway

The triterpene beta-amyrin inhibited 2-AG breakdown without directly binding to cannabinoid receptors, suggesting a new class of indirect cannabinoid-based pain relief.

Read this if you follow natural compound research and alternative approaches to cannabinoid-based pain relief.

No CB receptor binding, contradicting prior claims of sub-nanomolar affinity

What the researchers found

Previous research claimed the natural triterpenes alpha- and beta-amyrin bound directly to CB1 receptors at subnanomolar concentrations and relieved pain through cannabinoid receptors. This study challenged that finding.

Using validated binding assays, the researchers found no binding of either amyrin to human CB1 or CB2 receptors (Ki values greater than 10 micromolar, compared to the previously claimed 133 picomolar). Instead, beta-amyrin potently inhibited the breakdown of 2-AG (an endocannabinoid) without affecting anandamide breakdown.

Beta-amyrin only weakly inhibited purified MAGL but more potently inhibited 2-AG breakdown in cell and brain homogenates, suggesting it targeted multiple alpha,beta-hydrolases involved in 2-AG metabolism.

Why it matters

This study corrected the scientific record while uncovering a potentially more interesting mechanism: a natural compound that relieves pain by indirectly boosting endocannabinoids rather than directly activating cannabinoid receptors. This could avoid psychoactive side effects.

The numbers in context

No CB receptor binding (Ki > 10 micromolar vs previously claimed 133 pM). Beta-amyrin potently inhibited 2-AG hydrolysis. Weak inhibition of purified MAGL but potent inhibition in tissue homogenates.

How the study worked

In vitro pharmacology study using validated CB receptor binding assays (hCB1 and hCB2 transfected CHO-K1 cells), endocannabinoid transport assays, and enzyme activity measurements with both purified enzymes and cell/tissue homogenates.

What this study cannot tell us

In vitro study only. The discrepancy with previous binding data was unexplained. The mechanism of 2-AG protection in tissue homogenates (beyond MAGL) was not fully characterized. No in vivo validation was included.

How to read the evidence

In vitro pharmacology study that corrected previous findings and identified a new mechanism. Well-controlled but lacks in vivo validation.

When this study was published

Published in 2012. Triterpene research for pain management has continued as a niche area of investigation.

The bigger picture

Triterpenes are widely distributed in plants and already consumed in human diets. If they can boost endocannabinoid tone indirectly, they represent a new scaffold for developing non-psychoactive pain medications that work through the cannabinoid system.

Questions still open

Which specific hydrolases does beta-amyrin target beyond MAGL? Can triterpene-based drugs be developed for clinical pain management? Why did previous studies report direct CB1 binding?

Common questions

Could this plant compound replace cannabis for pain?

Beta-amyrin works differently from cannabis: rather than directly activating cannabinoid receptors, it boosts the body's own endocannabinoids by preventing their breakdown. This could provide pain relief without the high, but this study was only in test tubes, not in people.

Why does it matter that previous binding claims were wrong?

Accurate understanding of how a compound works is essential for drug development. If beta-amyrin works by boosting endocannabinoids rather than directly activating receptors, the drug development strategy would be completely different.

Read the original research

The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors.

British journal of pharmacology, 167(8), 1596-608

View on PubMed ↗Publisher’s paper ↗

Citation

Chicca, A; Marazzi, J; Gertsch, J. (2012). The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors.. British journal of pharmacology, 167(8), 1596-608. https://doi.org/10.1111/j.1476-5381.2012.02059.x